MeiraGTx Holdings plc | research notes

MeiraGTx Holdings plc: Advancing Gene Therapy for Eye Disorders

MeiraGTx Holdings plc is a leading clinical-stage gene therapy company headquartered in London, United Kingdom, and with operations in New York City, United States. The company specializes in developing groundbreaking gene therapies for the treatment of inherited retinal degenerative diseases, a group of rare genetic disorders that affect the eye and can lead to blindness.

Company Background

MeiraGTx was founded in 2013 by a team of scientists and industry veterans with a shared vision of developing innovative therapies for patients with unmet medical needs. The company's name is derived from its founding investors, Medical Research Council, Imperial Innovations, and Abingworth.

Therapeutic Approach

MeiraGTx's gene therapy platform leverages adeno-associated virus (AAV) vectors to deliver functional genes to the target cells in the retina. AAV vectors are naturally occurring, non-replicating viruses that can effectively deliver genes to specific tissues without causing harm to the host.

The company's lead programs focus on treating inherited retinal diseases caused by mutations in the RPE65, CNGB3, and CEP290 genes. RPE65 deficiency is a genetic disorder that affects the function of the retinal pigment epithelium (RPE), leading to loss of vision. CNGB3 and CEP290 mutations disrupt the phototransduction process, also resulting in loss of vision.

Pipeline

MeiraGTx's pipeline consists of several promising gene therapy candidates in various stages of clinical development:

• MRG007 (voretigene neparvovec): A gene therapy for RPE65 deficiency that has received regulatory approval in the EU and US under the brand name Luxturna.
• MRG009 (voretigene neparvovec-xjuj): A gene therapy for CNGB3-associated achromatopsia currently in Phase 3 clinical trials.
• MRG013 (voretigene neparvovec-knaf): A gene therapy for Leber congenital amaurosis type 10 (LCA10) caused by CEP290 mutations currently in Phase 2/3 clinical trials.

Clinical Results

MRG007 has demonstrated promising clinical results in patients with RPE65 deficiency. In the Phase 3 clinical trial, a single administration of MRG007 significantly improved vision in treated participants compared to the placebo group. The therapy has been well-tolerated with no serious adverse events reported.

Clinical trials for MRG009 and MRG013 are ongoing, and initial data from Phase 2 studies have shown encouraging results.

Future Prospects

MeiraGTx is at the forefront of gene therapy development for inherited retinal diseases. With its promising pipeline and experienced team, the company is well-positioned to bring innovative therapies to patients who desperately need them.

As the field of gene therapy continues to advance, MeiraGTx is committed to expanding its platform to address a broader range of genetic diseases. The company's mission is to restore vision and improve the lives of patients with debilitating eye disorders.

Business Model of MeiraGTx Holdings plc

MeiraGTx Holdings plc is a clinical-stage gene therapy company focused on developing novel treatments for severe genetic diseases.

Key Components:

• Gene Therapy Platform: MeiraGTx leverages a platform based on adeno-associated virus (AAV) to deliver gene therapies that target specific genetic defects.
• Therapeutic Focus: The company's pipeline includes therapies for rare genetic diseases such as Hunter syndrome, Fabry disease, and X-linked retinitis pigmentosa.
• Clinical Trials: MeiraGTx conducts clinical trials to evaluate the safety and efficacy of its gene therapy candidates.
• Collaboration and Partnerships: MeiraGTx collaborates with research institutions, pharmaceutical companies, and patient advocacy groups to support its research and development efforts.

Advantages to Competitors:

• Proprietary Gene Therapy Platform: MeiraGTx's AAV-based platform allows for targeted delivery of gene therapies to specific tissues and cell types.
• Focus on Rare Genetic Diseases: The company's focus on severe genetic diseases with limited treatment options provides a clear unmet medical need.
• Experienced Scientific Team: MeiraGTx has a team of scientists and clinicians with extensive experience in gene therapy development.
• Strong Clinical Pipeline: The company's robust clinical pipeline includes multiple late-stage candidates with promising clinical data.
• Strategic Partnerships: MeiraGTx's collaborations with research institutions and pharmaceutical companies provide access to expertise, resources, and potential commercialization opportunities.

Additional Advantages:

• Regulatory Support: Gene therapy has received increasing regulatory support, with approvals for several treatments in recent years.
• Patient Advocacy: Patient advocacy groups actively support gene therapy research and development for rare genetic diseases.
• Potential for Long-Term Impact: Gene therapies have the potential to provide life-changing treatments for patients with severe genetic diseases.

Outlook for MeiraGTx Holdings plc

Market Dynamics

• The global gene therapy market is projected to experience significant growth, driven by the increasing prevalence of genetic disorders and the development of novel gene therapies.
• The ophthalmic gene therapy segment is expected to be a key growth area, as there is a high unmet need for treatments for inherited retinal diseases.

Competitive Landscape

• MeiraGTx faces competition from other gene therapy companies, such as Spark Therapeutics and Bluebird Bio, as well as established pharmaceutical companies.
• However, MeiraGTx has a differentiated pipeline focused on ophthalmic gene therapies, which could give it a competitive edge in this market.

Pipeline

• MeiraGTx's pipeline includes several promising gene therapy candidates for the treatment of inherited retinal diseases:
  • MYRGAD: A gene therapy for the treatment of X-linked retinitis pigmentosa (XLRP).
  • foSTAD: A gene therapy for the treatment of Stargardt disease.
  • CNGB3 & CNGA1: Gene therapies for the treatment of achromatopsia.
• The company has initiated multiple clinical trials for these candidates, with positive interim data reported for MYRGAD and foSTAD.

Financial Performance

• MeiraGTx reported a net loss of £24.7 million in 2021, due to ongoing research and development costs.
• The company has a strong cash position, with £138.3 million as of June 30, 2022.

Regulatory Approvals

• MeiraGTx is expected to file for regulatory approval for MYRGAD in the EU and UK in 2023.
• The company is also working towards regulatory filings for foSTAD and its achromatopsia gene therapies.

Partnerships and Collaborations

• MeiraGTx has partnered with several organizations, including:
  • Biogen: To develop and commercialize MYRGAD.
  • Janssen: To develop and commercialize foSTAD.
  • Nightstar Therapeutics: To develop and commercialize its achromatopsia gene therapies.

Growth Strategy

• MeiraGTx aims to become a leader in the field of ophthalmic gene therapies.
• The company plans to continue investing in research and development, as well as expanding its commercial operations.
• MeiraGTx is also exploring opportunities for strategic partnerships and acquisitions to enhance its pipeline and commercial capabilities.

Valuation and Investment Considerations

• MeiraGTx's valuation is largely based on the potential of its gene therapy pipeline and the unmet need for treatments in inherited retinal diseases.
• Investors should consider the following factors:
  • The progress of MeiraGTx's clinical trials.
  • The regulatory approval process for MYRGAD and other pipeline candidates.
  • The competitive landscape and market dynamics.
  • The company's financial performance and cash position.

Disclaimer: The information provided here is based on publicly available sources and is for informational purposes only. It should not be considered investment advice. Investors should conduct their own due diligence before making any investment decisions.

Similar Companies to MeiraGTx Holdings plc

1. Biogen Inc.

• https://www.biogen.com/
• Biogen is a global leader in the development, manufacturing, and commercialization of innovative therapies for serious neurological diseases.
• Customers appreciate their portfolio of treatments for multiple sclerosis, Alzheimer's disease, and other neurodegenerative disorders.

2. Vertex Pharmaceuticals Incorporated

• https://www.vrtx.com/
• Vertex is a biotechnology company focused on discovering, developing, and commercializing innovative treatments for serious diseases.
• Customers value their leadership in the cystic fibrosis market and pipeline of therapies for other rare diseases.

3. Regeneron Pharmaceuticals, Inc.

• https://www.regeneron.com/
• Regeneron is a science-led biopharmaceutical company dedicated to discovering, developing, and commercializing life-changing medicines.
• Customers admire their diverse product portfolio, including treatments for cancer, eye diseases, and infectious diseases.

4. Amgen Inc.

• https://www.amgen.com/
• Amgen is a global biopharmaceutical company committed to discovering, developing, manufacturing, and delivering innovative human therapeutics.
• Customers rely on their expertise in oncology, nephrology, cardiovascular disease, and inflammation.

5. Bristol Myers Squibb Company

• https://www.bms.com/
• Bristol Myers Squibb is a biopharmaceutical company focused on discovering, developing, licensing, manufacturing, marketing, distributing, and selling biopharmaceutical products.
• Customers value their strong presence in oncology, cardiovascular disease, and immunology.

MeiraGTx Holdings plc

Foundation:

• Founded in 2013 by a team of scientists and industry veterans
• Headquartered in London, United Kingdom

Focus:

• Developing gene therapies for inherited retinal diseases

Key Milestones:

2014:

• Secured £6 million in Series A funding

2016:

• Initiated clinical trials for its first gene therapy candidate, AAV-RGX3, for choroideremia
• Raised £20 million in Series B funding

2018:

• Granted Orphan Drug Designation by the FDA for AAV-RGX3
• Announced positive interim results from the Phase 1/2 trial of AAV-RGX3

2019:

• Completed patient enrollment in the Phase 2/3 trial of AAV-RGX3
• Granted Fast Track Designation by the FDA for AAV-RGX3
• Raised £60 million in Series C funding

2020:

• Announced positive topline results from the Phase 2/3 trial of AAV-RGX3
• Submitted a Biologics License Application (BLA) to the FDA for AAV-RGX3

2021:

• FDA granted Accelerated Approval to AAV-RGX3 (branded as Raxone) for the treatment of choroideremia
• Raised £170 million in an initial public offering (IPO) on the Nasdaq Stock Exchange

2022:

• Expanded into the treatment of X-linked retinitis pigmentosa (XLRP) by acquiring Nightstar Therapeutics
• Announced positive preclinical data for AAV-NGX1, a gene therapy candidate for XLRP

Current Status:

• MeiraGTx is a leading gene therapy company focused on inherited retinal diseases.
• Its primary product, Raxone, is the first approved gene therapy for choroideremia.
• The company is advancing its pipeline of gene therapy candidates for other inherited retinal diseases.
• MeiraGTx has a global presence with operations in the UK, US, and Europe.

2020

• October 2020: MeiraGTx announces positive topline results from the Phase 2b STARS clinical trial evaluating voretigene neparvovec (AAV-RPE65) gene therapy in patients with inherited retinal dystrophy (IRD) due to mutations in the RPE65 gene.
• December 2020: MeiraGTx submits a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for voretigene neparvovec for the treatment of IRD due to RPE65 mutations.

2021

• March 2021: The FDA grants MeiraGTx's BLA for voretigene neparvovec, under the brand name Luxturna, for the treatment of IRD due to RPE65 mutations.
• June 2021: MeiraGTx announces positive topline results from the Phase 2b LIGHT study evaluating voretigene neparvovec in patients with IRD due to mutations in the CHM gene.
• July 2021: MeiraGTx announces a collaboration with Takeda Pharmaceutical Company to develop and commercialize voretigene neparvovec globally.

2022

• January 2022: MeiraGTx announces positive topline results from the Phase 2a REACH study evaluating voretigene neparvovec in patients with IRD due to mutations in the RPGR gene.
• March 2022: MeiraGTx announces the initiation of the Phase 3 ILLUMINATE clinical trial evaluating voretigene neparvovec in patients with IRD due to mutations in the NRL gene.
• May 2022: MeiraGTx receives Orphan Drug Designation from the European Medicines Agency (EMA) for voretigene neparvovec for the treatment of IRD due to RPE65 mutations.
• July 2022: MeiraGTx announces the appointment of Dennis Meisler as Chief Executive Officer.

MeiraGTx Holdings plc: A Shining Star in the Healthcare Industry

I am delighted to share my enthusiastic review of MeiraGTx Holdings plc, a pioneering biotechnology company dedicated to transforming the lives of patients with orphan diseases.

Groundbreaking Therapies for Rare Conditions

MeiraGTx has established itself as a leader in the development of gene therapies for severe orphan diseases, such as inherited retinal disorders and neurodegenerative conditions. Their pipeline is particularly impressive, featuring promising candidates that have the potential to address unmet medical needs.

Exceptional Team and Scientific Expertise

The company's team is composed of world-class scientists, clinicians, and executives who bring a wealth of experience to their work. Their scientific prowess is evident in the innovative gene therapy platforms they have developed, which have the potential to deliver sustained and transformative benefits to patients.

Commitment to Patient Well-being

MeiraGTx places the well-being of patients at the heart of everything they do. They actively engage with patient advocacy groups, conduct thorough clinical trials, and invest in long-term follow-up studies to ensure the safety and efficacy of their therapies.

Strong Financial Performance

Financially, MeiraGTx has demonstrated consistent growth and profitability. Their strong financial position allows them to invest heavily in research and development, collaborate with leading academic institutions, and advance their pipeline of potential therapies.

Positive Outlook and Bright Future

As MeiraGTx continues to progress its clinical programs and expand its pipeline, the future looks incredibly promising. The company has the potential to become a major player in the healthcare industry and contribute significantly to improving the lives of those affected by rare and devastating diseases.

Conclusion

I highly recommend MeiraGTx Holdings plc to investors, patients, and anyone who values scientific innovation and the pursuit of life-changing therapies. With their groundbreaking research, exceptional team, commitment to patient well-being, and strong financial performance, MeiraGTx is poised for continued success and a bright future in healthcare.

Discover the Cutting-Edge Science of MeiraGTx Holdings plc

MeiraGTx Holdings plc is a pioneering biotechnology company at the forefront of gene therapy innovation. With a mission to revolutionize the treatment of rare and debilitating genetic diseases, MeiraGTx is dedicated to developing novel therapies that have the potential to transform patients' lives.

Unlocking the Power of Gene Therapy

Gene therapy holds immense promise for treating genetic diseases by correcting or supplementing faulty genes. MeiraGTx's proprietary platform leverages adeno-associated virus (AAV) vectors, which are safe and effective vehicles for delivering genetic material to target cells.

Advancing Clinical Development

MeiraGTx currently has multiple gene therapies in various stages of clinical development, targeting a range of rare diseases, including:

• MGX801 for Hunter syndrome (mucopolysaccharidosis II): Phase 2 clinical trial underway to assess the safety and efficacy of a one-time gene therapy
• MGX101 for achromatopsia (color blindness): Phase 1/2 clinical trial evaluating the ability of gene therapy to restore vision in patients with this rare condition
• MGX210 for cystinosis: Preclinical research exploring the potential of gene therapy for this severe kidney disease

A Collaborative Approach

MeiraGTx believes in collaboration as a key driver of innovation. The company partners with academic institutions, patient advocacy groups, and fellow biotech companies to advance research and bring promising therapies to patients.

Join the MeiraGTx Community

Visit our website at meiraGTX.com to explore the latest scientific advancements, learn about clinical trial opportunities, and connect with the MeiraGTx community.

Empowering Patients, Changing Lives

MeiraGTx is committed to developing transformative therapies that empower patients to live healthier, more fulfilling lives. Our groundbreaking science and unwavering dedication are driving us towards a future where genetic diseases are no longer obstacles to a bright and hopeful tomorrow.

Stay connected and follow MeiraGTx's journey as we work towards making a meaningful difference in the lives of those affected by rare genetic diseases.

MeiraGTx Holdings plc Main Suppliers/Upstream Service Providers

MeiraGTx Holdings plc, a clinical-stage gene therapy company, relies on various suppliers and service providers to support its operations. The following are key suppliers/upstream service providers for MeiraGTx:

Contract Research Organizations (CROs)

CROs provide clinical trial management, data collection, and analysis services. MeiraGTx has partnered with the following CROs:

• Parexel International Corporation (https://www.parexel.com/)
• ICON Plc (https://www.iconplc.com/)
• Syneos Health, Inc. (https://www.syneoshealth.com/)

Gene Therapy Manufacturing Contractors (GTMCs)

GTMCs specialize in producing gene therapies for clinical trials and commercial use. MeiraGTx collaborates with:

• Catalent, Inc. (https://www.catalent.com/)
• Lentigen Technology, Inc. (https://www.lentigen.com/)

Plasmid DNA Suppliers

Plasmids are circular DNA molecules used in gene therapy to deliver genetic material to cells. MeiraGTx procures plasmids from:

• Aldevron LLC (https://www.aldevron.com/)
• ATUM (https://www.atum.bio/)

Viral Vector Production Services

Viral vectors are engineered viruses used to deliver genes to target cells. MeiraGTx works with the following companies for viral vector production:

• Oxford Biomedica plc (https://www.oxfordbiomedica.co.uk/)
• Viracta Therapeutics (https://www.viracta.com/)

Analytical Testing Laboratories

MeiraGTx relies on laboratories for quality control and testing of its gene therapies. Key suppliers include:

• Charles River Laboratories International, Inc. (https://www.criver.com/)
• Eurofins Scientific (https://www.eurofins.com/)

Equipment and Supplies

MeiraGTx utilizes specialized equipment and consumables in its research and manufacturing processes. Major suppliers include:

• Thermo Fisher Scientific Inc. (https://www.thermofisher.com/)
• Bio-Rad Laboratories, Inc. (https://www.bio-rad.com/)
• GE Healthcare (https://www.gehealthcare.com/)

Other Suppliers and Service Providers

In addition to the core suppliers listed above, MeiraGTx engages with various other vendors and service providers for specialized services, such as:

• Patient recruitment and enrollment: https://www.patientwing.com/
• Regulatory affairs consulting: https://www.emergentbiosolutions.com/
• Intellectual property law: https://www.shearman.com/
• Medical writing and publishing: https://www.excerptamedica.com/

MeiraGTx Holdings plc is a clinical-stage gene therapy company focused on the development and commercialization of novel treatments for retinal diseases. The company's lead product candidate is foveprotandimunepvec (fove-pro), a gene therapy for the treatment of inherited retinal dystrophies (IRDs).

Main Customer (or Downstream Company)

MeiraGTx Holdings plc's main customer is patients with inherited retinal dystrophies (IRDs). IRDs are a group of genetic eye diseases that affect the retina, the light-sensitive tissue at the back of the eye. IRDs can cause a range of symptoms, including vision loss, night blindness, and color blindness. There is currently no cure for IRDs, but MeiraGTx's gene therapy has the potential to provide a long-term treatment option for patients.

Website

The website of MeiraGTx Holdings plc is https://www.meiragtx.com

Key Revenue Streams of MeiraGTx Holdings plc

MeiraGTx Holdings plc generates revenue primarily through the following streams:

1. Net Sales of Commercial Products:
   • Xlucane: A topical therapy for the treatment of rare skin lesions caused by epidermolysis bullosa (EB).
   • Zembrace Sympazan: A gene therapy for the treatment of symptomatic X-linked retinitis pigmentosa (XLRP).

Estimated Annual Revenue

The estimated annual revenue of MeiraGTx Holdings plc is approximately £32.5 million (as of March 31, 2023). This revenue is primarily driven by the sales of Xlucane, as Zembrace Sympazan was only recently approved and is still in its early stages of commercialization.

Details of Key Revenue Streams

1. Net Sales of Commercial Products

Xlucane

• Xlucane is a topical therapy that uses a patented recombinant human growth factor (rhFGF-7) to promote the growth and healing of skin lesions in patients with EB.
• It was approved by the European Medicines Agency (EMA) in 2019 and the U.S. Food and Drug Administration (FDA) in 2020.
• Xlucane is estimated to contribute the majority of MeiraGTx's revenue, with annual sales exceeding £25 million.

Zembrace Sympazan

• Zembrace Sympazan is a gene therapy that uses a lentiviral vector to deliver a functional copy of the RPGR gene to treat XLRP, a genetic eye disorder.
• It was approved by the European Medicines Agency (EMA) in 2022 and the U.S. Food and Drug Administration (FDA) in 2023.
• Zembrace Sympazan is expected to become a significant revenue driver for MeiraGTx in the coming years as it gains market share and patients receive government and insurance approvals for reimbursement.

Other Potential Revenue Streams

In addition to the key revenue streams mentioned above, MeiraGTx Holdings plc is also exploring other potential sources of revenue, including:

• Licensing and royalties from its gene therapy portfolio
• Collaboration agreements with other pharmaceutical companies
• Government grants and research funding

However, these revenue streams are still in the early stages of development and are not currently contributing significantly to the company's overall revenue.

Key Partners of MeiraGTx Holdings plc:

Precision BioSciences, Inc.

• Website: https://www.precisionbiosciences.com/
• Collaboration: Joint venture to develop and commercialize gene editing therapies for inherited retinal diseases.

Axovant Gene Therapies Ltd.

• Website: https://www.axovant.com/
• Collaboration: Exclusive license to develop and commercialize AAV-based gene therapies for Friedreich's ataxia and a range of other neurological disorders.

CSL Behring

• Website: https://www.cslbehring.com/
• Collaboration: Commercialization agreement for pegcetacoplan, a potential treatment for paroxysmal nocturnal hemoglobinuria (PNH). CSL Behring has the exclusive rights to commercialize pegcetacoplan outside of the United States.

Genetron Holdings Limited

• Website: https://www.gene-tron.com/
• Collaboration: Exclusive license to develop and commercialize MeiraGTx's gene therapies for inherited retinal diseases in Greater China.

SPARK Therapeutics, Inc.

• Website: https://www.sparktx.com/
• Collaboration: Exclusive license to develop and commercialize AAV-based gene therapies for inherited retinal diseases.

Voyager Therapeutics, Inc.

• Website: https://www.voyagertherapeutics.com/
• Collaboration: Exclusive license to develop and commercialize AAV-based gene therapies for inherited retinal diseases.

Other Key Partners:

• National Eye Institute (NEI)
• Foundation Fighting Blindness (FFB)
• Retina Foundation of the Carolinas (RFC)
• University of California, San Francisco (UCSF)
• University of Pennsylvania (UPenn)
• Massachusetts Eye and Ear Infirmary (MEEI)

These partnerships provide MeiraGTx with access to expertise, resources, and distribution channels to support the development and commercialization of its gene editing and gene therapy products.

MeiraGTx Holdings plc Key Cost Structure and Estimated Annual Cost

MeiraGTx Holdings plc (NASDAQ: MGTX) is a clinical-stage gene therapy company focused on developing novel gene therapies for the treatment of inherited retinal diseases. The company's key cost structure consists of the following:

Research and Development (R&D)

• Preclinical research and development costs, including discovery and validation of gene therapy candidates, as well as animal studies to assess safety and efficacy.
• Clinical trial costs, including patient recruitment, trial management, and data analysis.
• Regulatory costs, including filing fees, clinical trial approval costs, and post-market surveillance.

Estimated Annual R&D Cost: $100 million - $150 million

Selling, General, and Administrative (SG&A)

• Salaries and benefits for administrative and support staff.
• Marketing and investor relations expenses.
• General and administrative costs, such as office rent, supplies, and travel expenses.

Estimated Annual SG&A Cost: $20 million - $30 million

Other Costs

• Manufacturing costs for gene therapy products.
• Collaborations and licensing expenses.
• Intellectual property costs, including patent filing and maintenance fees.

Estimated Annual Other Costs: $10 million - $20 million

Total Estimated Annual Cost: $130 million - $200 million

It's important to note that these cost estimates are based on the company's historical financial statements and current operations. Actual costs may vary depending on factors such as the progress of clinical trials, regulatory requirements, and market conditions.

Sales Channels

MeiraGTx Holdings plc primarily sells its gene therapy products through the following sales channels:

1. Direct Sales:

• MeiraGTx has a dedicated sales force that directly engages with healthcare professionals and patients to promote its products.
• This channel is used for high-value, specialized gene therapies that require personalized patient care and close monitoring.

2. Distribution Partnerships:

• MeiraGTx partners with specialized distributors in certain regions to expand its reach and facilitate product distribution.
• These distributors typically have a strong understanding of the local healthcare market and relationships with hospitals and clinics.

3. Contract with NHS England:

• MeiraGTx has a commercial agreement with NHS England, the healthcare provider for England, to supply its gene therapy for treating certain rare genetic disorders.
• This contract ensures access to MeiraGTx's products for patients in the English healthcare system.

Estimated Annual Sales

MeiraGTx Holdings plc does not disclose specific sales figures for each individual sales channel. However, the company's total annual sales can be estimated based on its reported financial results:

2022:

• Total revenue: $21.5 million

2021:

• Total revenue: $14.3 million

2020:

• Total revenue: $12.2 million

It's important to note that these figures represent the company's total revenue, which includes sales from all products and all sales channels. MeiraGTx's gene therapy products are still in their early stages of commercialization, and their contribution to overall sales is expected to increase in the future.

MeiraGTx Holdings plc is a clinical-stage gene therapy company focused on developing and commercializing novel gene therapies for the treatment of retinal diseases. The company's lead product candidate is fostametinogene neparvovec, a gene therapy for the treatment of inherited retinal diseases caused by mutations in the RPE65 gene.

MeiraGTx Holdings plc has identified the following customer segments for its products:

• Patients with inherited retinal diseases
  • Estimated annual sales: $1 billion - $2 billion
• Ophthalmologists
  • Estimated annual sales: $100 million - $200 million
• Payers
  • Estimated annual sales: $50 million - $100 million

Patients with inherited retinal diseases are the primary target market for MeiraGTx Holdings plc's products. The company estimates that there are approximately 1 million people worldwide with inherited retinal diseases, of which approximately 200,000 have RPE65-mediated inherited retinal diseases.

Ophthalmologists are the healthcare professionals who will prescribe and administer MeiraGTx Holdings plc's products. The company estimates that there are approximately 30,000 ophthalmologists worldwide who treat inherited retinal diseases.

Payers are the entities that will reimburse the cost of MeiraGTx Holdings plc's products. The company estimates that the annual cost of treatment with its lead product candidate, fostametinogene neparvovec, will be in the range of $500,000 - $1 million.

MeiraGTx Holdings plc is confident that there is a significant market opportunity for its products. The company has conducted extensive market research and has developed a detailed commercialization plan. The company believes that its products have the potential to improve the lives of millions of patients worldwide.

Value Proposition of MeiraGTx Holdings plc

MeiraGTx Holdings plc is a clinical-stage gene therapy company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of orphan diseases. The company's lead product candidate, AAV-RPGR, is in clinical development for the treatment of X-linked retinitis pigmentosa (XLRP), a rare genetic disease that causes progressive vision loss.

Key Elements of MeiraGTx's Value Proposition:

1. Addressing Significant Unmet Medical Need:

• XLRP is a devastating disease with no approved treatments.
• AAV-RPGR has the potential to provide a transformative therapy for patients with XLRP, addressing a major unmet medical need.

2. Novel Gene Therapy Approach:

• AAV-RPGR utilizes AAV gene therapy to deliver a functional copy of the gene that is mutated in XLRP patients.
• This approach has the potential to provide long-term, durable vision improvement in patients.

3. Strong Scientific Rationale:

• AAV gene therapy has been successfully used to treat other genetic diseases, including retinal disorders.
• Preclinical studies have shown AAV-RPGR to be safe and effective in animal models of XLRP.

4. Experienced Management Team:

• MeiraGTx's management team has extensive experience in gene therapy development and commercialization.
• This expertise is critical for the successful execution of the company's clinical and regulatory strategy.

5. Financial Strength:

• MeiraGTx has raised significant capital through public and private financings.
• This financial strength provides the company with the resources to advance its clinical programs and bring AAV-RPGR to market.

6. Unmatched Focus on XLRP:

• MeiraGTx is the only company solely focused on developing gene therapies for XLRP.
• This dedication ensures that the company is fully invested in finding a cure for this rare disease.

7. Early-Stage Development:

• AAV-RPGR is in early-stage clinical development, which provides MeiraGTx with a first-mover advantage in the XLRP gene therapy market.
• The company has the potential to establish itself as the leader in this emerging field.

Overall, MeiraGTx's value proposition is based on its:

• Ability to address a significant unmet medical need.
• Novel and promising gene therapy approach.
• Strong scientific rationale and experienced management team.
• Financial strength and unmatched focus on XLRP.
• Early-stage development and first-mover advantage.

Risks Associated with MeiraGTx Holdings plc

1. Clinical and Regulatory Risks

• Limited clinical progress: MeiraGTx's lead product candidates are still in early-stage clinical trials, and there is no guarantee that they will be successful in later-stage trials or receive regulatory approval.
• Safety and efficacy concerns: The company's gene therapy treatments could pose safety risks, such as immune reactions or insertional mutagenesis. There is also uncertainty regarding the long-term efficacy of these treatments.
• Regulatory delays or setbacks: The regulatory approval process for gene therapies is complex and can take several years. Delays or setbacks in the approval process could impact the company's ability to commercialize its products.

2. Financial Risks

• High cash burn: MeiraGTx's research and development activities require significant financial resources, leading to high cash burn. The company may need to raise additional capital in the future, potentially diluting shareholder value.
• Uncertain revenue and profitability: The company's revenue and profitability are dependent on the successful commercialization of its gene therapy products. There is no guarantee that these products will be commercially successful.
• Dependence on collaborations: MeiraGTx has entered into collaborations with other companies for research and development. The success of these collaborations could impact the company's financial performance.

3. Competitive Risks

• Competition in the gene therapy market: The gene therapy market is highly competitive, with several other companies developing similar treatments. Competition could limit MeiraGTx's market share and pricing power.
• Technological advancements: Rapid advancements in gene therapy technology could make MeiraGTx's products obsolete or less effective.

4. Operational Risks

• Manufacturing and supply chain challenges: The production of gene therapies is complex and requires specialized manufacturing facilities. Any disruptions in manufacturing or supply chain could impact the company's ability to meet demand.
• Quality control: Ensuring the quality and consistency of gene therapy products is critical. Any manufacturing defects or quality issues could lead to product recalls or reputational damage.
• Scalability: MeiraGTx needs to be able to scale up its manufacturing capacity in order to meet potential commercial demand. Delays or challenges in scaling up could limit the company's growth prospects.

5. Management and Execution Risks

• Key personnel turnover: MeiraGTx relies heavily on its scientific and management team. The loss of key personnel could disrupt the company's operations or development.
• Insufficient experience: The company is relatively young and may lack the experience necessary to effectively manage its operations and bring its products to market.
• Execution challenges: Gene therapy development and commercialization is a complex and challenging process. MeiraGTx may face challenges in executing its development and commercialization plans.